Dynamic gadoxetate-enhanced MRI for the assessment of total and segmental liver function and volume in primary sclerosing cholangitis

Journal of Magnetic Resonance Imaging

Volumn 39, Issue 4, 2014, Pages 879-886

  Nilsson, Henrik ^a   Blomqvist, Lennart ^b   Douglas, Lena ^b   Nordell, Anders ^b   Jacobsson, Hans ^b   Hagen, Karin ^b   Bergquist, Annika ^b   Jonas, Eduard ^a  

^a Sweden Karolinska Institutet Department of Clinical Sciences Danderyd Hospital Stressrehab FoU Danderyd   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

DHCE MRI; Gd EOB DTPA; liver function; primary sclerosing cholangitis

Indexed keywords

GADOXETIC ACID;

ADULT; AGED; ARTICLE; CHOLANGIOGRAPHY; CHOLESTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; DYNAMIC HEPATOCYTE SPECIFIC CONTRAST ENHANCED NUCLEAR MAGNETIC RESONANCE IMAGING; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; LIVER BLOOD FLOW; LIVER CELL; LIVER FUNCTION; LIVER WEIGHT; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; YOUNG ADULT;

DHCE-MRI; GD-EOB-DTPA; LIVER FUNCTION; PRIMARY SCLEROSING CHOLANGITIS;

ADOLESCENT; ADULT; AGED; ALGORITHMS; CHOLANGITIS, SCLEROSING; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; LIVER; MALE; MIDDLE AGED; PATTERN RECOGNITION, AUTOMATED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84897026806     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.24250     Document Type: Article

References (21)

1. Wiesner RH,. Liver transplantation for primary sclerosing cholangitis: timing, outcome, impact of inflammatory bowel disease and recurrence of disease. Best Pract Res Clin Gastroenterol 2001; 15: 667-680.
2. Karlsen TH, Schrumpf E, Boberg KM,. Primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2010; 24: 655-666.
3. Kim WR, Therneau TM, Wiesner RH, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000; 75: 688-694.
4. de Graaf W, Hausler S, Heger M, et al. Transporters involved in the hepatic uptake of (99m)Tc-mebrofenin and indocyanine green. J Hepatol 2011; 54: 738-745.
5. Narita M, Hatano E, Arizono S, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009; 44: 793-798.
6. Kitao A, Zen Y, Matsui O, et al. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging - correlation with molecular transporters and histopathologic features. Radiology 2010; 256: 817-826.
7. Leonhardt M, Keiser M, Oswald S, et al. Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metab Dispos 2010; 38: 1024-1028.
8. Hamm B, Staks T, Muhler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995; 195: 785-792.
9. Nilsson H, Blomqvist L, Douglas L, Nordell A, Jonas E,. Assessment of liver function in primary biliary cirrhosis using Gd-EOB-DTPA-enhanced liver MRI. HPB (Oxford) 2010; 12: 567-576.
10. Strasberg SM,. Terminology of liver anatomy and liver resections: coming to grips with hepatic Babel. J Am Coll Surg 1997; 184: 413-434.
11. Nilsson H, Nordell A, Vargas R, Douglas L, Jonas E, Blomqvist L,. Assessment of hepatic extraction fraction and input relative blood flow using dynamic hepatocyte-specific contrast-enhanced MRI. J Magn Reson Imaging 2009; 29: 1323-1331.
12. Brown PH, Juni JE, Lieberman DA, Krishnamurthy GT,. Hepatocyte versus biliary disease: a distinction by deconvolutional analysis of technetium-99m IDA time-activity curves. J Nucl Med 1988; 29: 623-630.
13. Berstad AE, Aabakken L, Smith HJ, Aasen S, Boberg KM, Schrumpf E,. Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2006; 4: 514-520.
14. Jacobsson H, Jonas E, Hellstrom PM, Larsson SA,. Different concentrations of various radiopharmaceuticals in the two main liver lobes: a preliminary study in clinical patients. J Gastroenterol 2005; 40: 733-738.
15. Murakami T, Kim T, Gotoh M, et al. Experimental hepatic dysfunction: evaluation by MR imaging with Gd-EOB-DTPA. Acad Radiol 1998;(Suppl 1): S80-S82.
16. Ryeom HK, Kim SH, Kim JY, et al. Quantitative evaluation of liver function with MRI Using Gd-EOB-DTPA. Korean J Radiol 2004; 5: 231-239.
17. Yamada A, Hara T, Li F, et al. Quantitative evaluation of liver function with use of gadoxetate disodium-enhanced MR imaging. Radiology 2011; 260: 727-733.
18. Motosugi U, Ichikawa T, Sou H, et al. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging 2009; 30: 1042-1046.
19. Tschirch FT, Struwe A, Petrowsky H, Kakales I, Marincek B, Weishaupt D,. Contrast-enhanced MR cholangiography with Gd-EOB-DTPA in patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients with normal liver parenchyma. Eur Radiol 2008; 18: 1577-1586.
20. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237-267.
21. van Laarhoven HW, Rijpkema M, Punt CJ, et al. Method for quantitation of dynamic MRI contrast agent uptake in colorectal liver metastases. J Magn Reson Imaging 2003; 18: 315-320.